3Steps to Success

LEARN

LEARN

Peer-to-Peer GurU Training
On-Demand Courses
RHA^® Evaluation Day
Live Regional Training

LAUNCH

LAUNCH

Get Order-Ready / Update Inventory
Practice Locator Profile
Staff Training
Post on Social Media
Brand Your Practice

PROMOTE

PROMOTE

Host Your RHA^® Day
Social Media Best Practices
SEO Best Practices
Paid Social Media Best Practices
Email Best Practices

LEARN

Take time to learn what differentiates RHA^® from other fillers and how it will best serve you and your patients.

Attend

Peer-to-Peer RHA^® GurU Training

SIGN UP WITH YOUR PAC*

Log in

Take an on-demand course at your convenience

Schedule

Your RHA^® Evaluation

Participate

Live training opportunities in your region

CALL YOUR PAC
TO LEARN MORE

*PAC stands for Professional Aesthetic Consultant; an acronym used to refer to Revance’s sales representatives.

LAUNCH

Integrating a new product into your practice is a
little easier with a few reminders...

Get Order Ready

Setup your ordering portal with Customer Care

CALL CUSTOMER CARE
(877) 373-8669

Update Inventory

Add RHA^® to your management system

ADD RHA Redensity^TM
RHA^® 2, RHA^® 3,
RHA^® 4

RHA^® Practice Locator

Create or update your profile

Marketing Materials

Update practice materials so patients know you now offer the RHA^® Collection

Staff Training

Review Staff Talk Track with your PAC

Post on Social Media

Now offering the latest filler technology!

Brand Your Practice

Additional collateral available upon request

CALL YOUR PAC

Phew!

The logistics have been handled. Now, let’s move on to the FUN stuff!

Need anything else?
Your PAC is your partner

Reminder: PAC is
Revance’s lingo for
sales representative.

Quick Start

Begin your launch here with this selection of the RHA^® Collection’s most popular marketing assets

Promote

You’re an expert, you’re all set up, and now you’re ready to introduce your patients to the RHA® Collection!

Host Your RHA^® Day

An exclusive patient event to reveal the
RHA® Collection

An exclusive patient event to reveal the RHA^® Collection

Expand Your Reach

Going beyond your existing patient base

What's Next?

Quick Links

LEARN

LEARN

Log in to take an on-demand course or access RHA^® injection technique videos

Patient assessment and clinical guidance chart

LAUNCH

LAUNCH

Create or update your profile

Resources to help you inform your patients about the RHA^® Collection

Review the Staff Talk Track with your PAC as part of your staff training

Help people discover your social media content

PROMOTE

PROMOTE

Patient assessment and clinical guidance chart

Tips for hosting a successful event

Assets to help promote your event

Drive demand through social media

Master SEO to broaden awareness

Tips on how to utilize paid social media ads

Connect with your patients to keep your practice
top of mind

All trademarks are the property of their respective owners. ©2021 Revance Therapeutics, Inc. RHA-P-001344

Email Communication Best Practices

Do be certain that your RHA^® emails are optimized for mobile. 60% of email opens occur on smartphones or tablets. If your emails aren’t optimized for viewing on these devices, you’re potentially missing out on a huge number of clicks.
Do use irresistible subject lines. Speak to readers directly and promise them something that stands out from the other emails in their inbox. For example: “Camera On All Day with RHA^®!”
Do use an entertaining and distinctive voice. Just because readers open your email doesn’t mean they aren’t ready to quickly delete it. Always make sure your RHA^® message sounds like it came from a real person who cares.
Do segment your email lists by demographics. This makes it easier to create a message that resonates with your customers’ needs and generates interest in RHA^®.
Do use short paragraphs and be certain that keywords and phrases about RHA^® – such as “Flawless in Motion” – are relevant to your readers and stand out.
Do include bullet points to help people skim the content and take in vital points about RHA^®.
Do experiment with different subject lines, calls to action, and body text to see what is most engaging to your audience in addition to testing content on different platforms.
Do be aware of how often you send messages to your list. You don’t want to flood their inbox with marketing messages about RHA^® and your other offerings – they might get annoyed and unsubscribe.

Do not send emails to recipients without their permission.
Do not buy or acquire lists from other sources.
Do not send anything without making sure it’s working properly. Double-check that your RHA^® messages look the way you want them to be by sending them to employee accounts. Ideally, you will view them on Outlook.com, Gmail, and Yahoo, and on a variety of mobile devices before finalizing your drafts.
Do not send image-only emails. This shows poorly on mobile devices. Use a mix of RHA^® images and live text.
Do not use all caps, too many exclamation marks, and hyperbolic phrases – for example, “ACT NOW BEFORE TIME RUNS OUT!!!!” Poorly formatted HTML in your emails can also hurt how they’re handled. Every spam filter is different, so an email might pass through one filter but get flagged by another.

Pro Tip: Great email marketing ultimately comes down to giving your audience something that sticks with them – something that keeps RHA^® on their mind, whether that’s educational information, upcoming RHA^® events, or marketing messages about the products you offer, such as RHA^®.

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than glabellar lines. Expand to Read MoreExpand to Read More

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DAXXIFY^® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY^® is not approved for the treatment of spasticity or any conditions other than glabellar lines.

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

IMPORTANT SAFETY INFORMATION

Contraindications
DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect. The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Drug Interactions
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.
DAXI-001720.2

 PLEASE SEE FULL DIRECTIONS FOR USE
RHA® Collection of Fillers

Indications
The RHA® Collection of resilient hyaluronic acid (HA) fillers includes RHA Redensity™, RHA® 2, RHA® 3 and RHA® 4. RHA Redensity™ is indicated for injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids in adults 22 or older. RHA® 2 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds in adults 22 or older. RHA® 3 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds and is also indicated for injection into the vermillion body, vermillion border and oral commissure to achieve lip augmentation and lip fullness in adults 22 or older. RHA® 4 is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds in adults 22 or older.

IMPORTANT SAFETY INFORMATION

Contraindications
Do not use in patients who have severe allergies, marked by a history of anaphylaxis or multiple severe allergies, or in patients with a history of allergies to gram-positive bacterial proteins or local anesthetics of the amide type, such as lidocaine. Do not use in patients with bleeding disorders.

Warnings
Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur. Product use at specific sites in which an active inflammatory process or infection is present should be deferred until the underlying process has been controlled.

Precautions
These products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy. Discuss the potential risks of soft-tissue injections with your patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications. The safety and effectiveness for the treatment of anatomic regions other than the labeled indications have not been established in controlled U.S. clinical studies. As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Standard precautions associated with injectable materials should be followed. The safety for use in sites in the presence of other implants, during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied. Use with caution in patients on immunosuppressive therapy. Patients who are using products that can prolong bleeding (such as thrombolytics, anticoagulants, or inhibitors of platelet aggregation) may experience increased bruising or bleeding at treatment sites. Patients with a history of herpetic eruptions may experience reactivation of the herpes. There is a possible risk of inflammation at the implant site if laser treatments or a chemical peel are performed after treatment. Use as supplied. Modification or use of the product outside the Directions for Use may adversely impact the sterility, safety, homogeneity, or performance of the product. For single patient use. Do not reuse a syringe between two treatments and/or between two patients. Do not resterilize.

Adverse Events
The most commonly reported side effects were firmness, redness, tenderness, swelling, lumps/bumps, bruising, discoloration, pain and itching. Most of these events were mild or moderate and resolved within 14 days. Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own. To report an adverse reaction with any RHA^® product, please call Revance at (877) 373-8669.
RHA-P-002436.3

REFERENCES

DAXXIFY^®. Prescribing Information. Revance Therapeutics, Inc; 2022.
Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58.
BOTOX^® Cosmetic. Prescribing Information. Allergan, Inc; 2020.
Xeomin®. Prescribing Information. Merz Pharmaceuticals GmbH; 2021.
Dysport®. Prescribing Information. Ipsen Biopharmaceuticals, Ltd; 2020.
Jeuveau®. Prescribing Information. Evolus, Inc; 2020.
Fabi SG, Cohen JL, Green LJ, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. Dermatol Surg. 2020;47(1):48-54.
RHA^® Directions for Use. Nashville, TN: Revance Therapeutics, Inc, 2023.